SPOTLIGHT -
Professor of Medicine in Neurology, University of Ottawa; Director, Multiple Sclerosis Research Unit, Ottawa Hospital; Senior Scientist, Ottawa Hospital Research Institute
Do We Finally Have a Useful “Sed Rate” for Multiple Sclerosis?
All agree that having a simple, standardized serum biomarker to measure disease activity would offer the greatest utility in treating a medical condition such as MS, which now has a variety of graded therapies available.
The Future of Managing Multiple Sclerosis
Fumarates for Treatment of RMS
S1P Receptor Modulators for Treatment of RMS
Cladribine for Treatment of RMS
Anti-CD20 Monoclonal Antibodies for Treatment of RMS
Strategies for Choosing Initial Therapy in MS
OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue
TRIUMPHANT-MS Trial: Fatigue in MS
Multiple Sclerosis Fatigue
QoL Issues in the Management of Multiple Sclerosis
Challenges in Optimally Treating Multiple Sclerosis
Cerebrospinal Fluid in Diagnosing Multiple Sclerosis
Misdiagnosis of Multiple Sclerosis
Use of MRI in Diagnosing Multiple Sclerosis
2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis
Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative
COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results
CLARITY Extension Trial: Disability Improvement With Cladribine
Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial
Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study
Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting
Ozanimod Compared to Teriflunomide Utilizing Statistical Matching
OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data
OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance
Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide
Takeaways From ACTRIMS-ECTRIMS 2020 Meeting
Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies
OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS
OLKIOS: Looking at Ofatumumab’s Continued Efficacy